Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma …
B Tholander, A Taube, A Lindgren, O Sjöberg… - Gynecologic …, 1990 - Elsevier
Pretreatment serum levels of the antigens CA-125, tissue polypeptide Antigen (TPA),
Carcinoembryonic antigen (CEA), and placental alkaline phosphatase (PLAP) were …
Carcinoembryonic antigen (CEA), and placental alkaline phosphatase (PLAP) were …
CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a gynecologic oncology …
C Tian, M Markman, R Zaino, RF Ozols… - … Journal of the …, 2009 - Wiley Online Library
BACKGROUND: There are limited data regarding unique clinical or laboratory features
associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers …
associated with advanced clear cell (CC) and mucinous (MU) epithelial ovarian cancers …
[HTML][HTML] MUC16 mucin (CA125) regulates the formation of multicellular aggregates by altering β-catenin signaling
P Giannakouros, M Comamala, I Matte… - American journal of …, 2015 - ncbi.nlm.nih.gov
After shedding from the primary tumor site, ovarian cancer cells form three-dimensional
multicellular aggregates that serve as vehicle for cancer cell dissemination in the peritoneal …
multicellular aggregates that serve as vehicle for cancer cell dissemination in the peritoneal …
Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel
JA Bridgewater, AE Nelstrop, GJS Rustin… - Journal of clinical …, 1999 - ascopubs.org
PURPOSE: To assess CA-125 as a measure of response in patients treated with paclitaxel.
PATIENTS AND METHODS: One hundred forty-four patients treated with paclitaxel derived …
PATIENTS AND METHODS: One hundred forty-four patients treated with paclitaxel derived …
Prognostic value of CA125 kinetics and half-life in advanced ovarian cancer
S Čolaković, V Lukic, L Mitrovic, S Jelic… - … journal of biological …, 2000 - journals.sagepub.com
This retrospective study was undertaken in order to assess the prognostic value of
prechemotherapy serum CA125 level, CA125 kinetics, and CA125 half-life compared to the …
prechemotherapy serum CA125 level, CA125 kinetics, and CA125 half-life compared to the …
Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer
SC Rubin, WJ Hoskins, TB Hakes, M Markman… - American journal of …, 1989 - Elsevier
Serum CA 125 levels and surgical findings were prospectively compared in 96 secondary
laparotomies performed on patients with epithelial ovarian cancer. All patients had …
laparotomies performed on patients with epithelial ovarian cancer. All patients had …
[HTML][HTML] Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent …
I Matte, P Garde-Granger, P Bessette, A Piché - BMC cancer, 2019 - Springer
Background CA125 is a well-established ovarian cancer (OC) serum biomarker. The CA125
heavily glycosylated epitope is carried by the MUC16 mucin, a high molecular weight …
heavily glycosylated epitope is carried by the MUC16 mucin, a high molecular weight …
[HTML][HTML] Serum CA125 and ascites leptin level ratio predicts baseline clinical resistance to first-line platinum-based treatment and poor prognosis in patients with high …
I Matte, P Garde-Granger, P Bessette… - American Journal of …, 2019 - ncbi.nlm.nih.gov
About 20% of patients with high grade serous epithelial ovarian carcinoma (HGSOC) are
intrinsically resistant to standard first-line platinum-based combination therapy. There is no …
intrinsically resistant to standard first-line platinum-based combination therapy. There is no …
Use of CA-125 to predict survival of patients with ovarian carcinoma. North Thames Cooperative Group.
GJ Rustin, JN Gennings, AE Nelstrop… - Journal of Clinical …, 1989 - ascopubs.org
The prognostic value of serum CA-125 measurements was assessed in 54 patients with
advanced ovarian adenocarcinoma. All patients received a minimum of two courses of …
advanced ovarian adenocarcinoma. All patients received a minimum of two courses of …
A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas
R Molina, B Ojeda, X Filella, G Borras, J Jo, E Mas… - Tumor biology, 1992 - karger.com
In a prospective study, CA 125 and CA 19.9 serum levels were measured in 229 patients
with ovarian cancer [121 with active disease, 108 in complete remission (CR)], and in 20 …
with ovarian cancer [121 with active disease, 108 in complete remission (CR)], and in 20 …